Slide 1: Cover letter to stock exchanges
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Seriapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 09th February, 2024 To, T
Slide 2: Press Release: Alkem reports Q3FY24 and 9MFY24 results
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Seriapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Press Release Alkem repor
Slide 3: Operational Highlights: Domestic Business
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Seriapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Operational Highlights Do
Slide 4: International Business
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Seriapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 International Business In
Slide 5: Q3FY24 and 9MFY24 Conference Call
ALKEM LABORATORIES LTD. <8> ALKEM Regd, OffJce: AL.KEM HOUSE, Seriapali Bapal Marg, Lower Parsi (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q3FY24 and 9MFY24 Confere
Slide 6: Investor Presentation Q3FY24, February 9, 2024
Investor Presentation Q3FY24 February 9, 2024
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q3FY24
Key Highlights of Q3FY24 • EBITDA margin improved by 160 bps from 19.7% in Q3FY23 to 21.3% in Q3FY24. • EBITDA grew by 18.1% YoY from ₹ 5,990 mn to ₹ 7,076 mn • Revenue from Operation grew by 9.3% YoY during the quarter • India Business: As per IQVIA, Company’s sales in Q3FY24 registered growth of 8
Slide 9: Key Financial Highlights – Q3FY24 (Consolidated)
Key Financial Highlights – Q3FY24 (Consolidated) All figures in ₹ mn Revenue from Operations India sales 22,328 33,239 19,922 30,409 Q3FY23 Q3FY24 International sales 9,928 10,240 Q3FY23 Q3FY24 Q3FY23 Q3FY24
Slide 10: Key Financial Highlights – Q3FY24 (Consolidated)
Key Financial Highlights – Q3FY24 (Consolidated) All figures in ₹ mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 7,076 20,193 17,920 5,990 58.9% 60.8% 19.7% 21.3% Q3FY23 Q3FY24 Q3FY23 Q3FY24 PBT (before exceptional item) PAT (after Minority Interest) 5,950 7,062 4,547 5,389 Q3FY23 Q3FY24
Slide 11: Key Financial Highlights – 9MFY24 (Consolidated)
Key Financial Highlights – 9MFY24 (Consolidated) All figures in ₹ mn Particulars 9MFY24 9MFY23 YoY growth Revenue from Operations 97,318 86,967 11.9% Gross Profit 59,016 50,453 17.0% Gross Profit Margin 60.6% 58.0% EBITDA 18,435 12,562 46.8% EBITDA Margin 18.9% 14.4% PBT (before exceptional item) 17
Slide 12: India Business
India Business India Business: Q3FY24 Sales of ₹ 22,328 million (12.1% YoY growth) • Contribution of domestic sales to total sales in Q3FY24 was 68.6% • As per IQVIA, in Q3FY24, the Company’s secondary sales grew by 8.5% compared to IPM growth of 8.3% YoY. • Domestic business has witnessed strong pe
Slide 13: Secondary Sales Performance
Secondary Sales Performance Mixed performance across all major therapeutic segments in Q3FY24 1 3 3 2 Market rank Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Acute Therapies 14.1% 12.2% 9.5% 9.3% 8.2% 8.4% 6.9% 3.1% Alkem sales growth YoY1,2 Indian pharma indust
Slide 14: US Business
US Business US Business: Q3FY24 Sales of ₹ 6,838 million (10.2% YoY decline) • Overall contribution of US sales to total sales was 21% in Q3FY24 • During the quarter, the US business witnessed decline of 10.2% YoY on higher base of last year supported by flu season • During Q3FY24, the Company recei
Slide 15: US Business: Update on US FDA inspections
US Business Update on US FDA inspections Facility Capability Last inspection Status post last inspection Inspection done with 3 Form 483 observations. The Company Mandva (India) API December 2023 has already submitted a detailed response to the USFDA on the corrective and preventive actions being ta
Slide 16: Other International Business
Other International Business Other International Business: Q3FY24 Sales of ₹ 3,402 million (46.9% YoY growth) • Other International Market sales contributed 10.4% to total sales in Q3FY24 • Our Non-US business has contributed significantly amidst launch of limited competition products in our key foc
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 30, 2023 Non-Institution, 18.86% Promoter & Promoter Group, 56.74% Institution, 24.40% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 18: Thank You
Thank You For further information or queries, please contact Kunal Kothari GM Finance Tel: +91 22 3982 9999 E-mail: kunal.kothari@alkem.com